

# Pulmonary Circulation and Exercise: Friends or Foes?



Pr Vitalie FAORO

Laboratory of Cardio-Pulmonary Exercise Physiology (CPEP)  
Faculty of Motor Sciences (FSM), Université libre de Bruxelles (ULB)  
[Vitalie.Faoro@ulb.be](mailto:Vitalie.Faoro@ulb.be)



# PLAN

- Introduction
- High-Altitude
- Highlanders
- Moderate altitude
- Normoxia
- Athletes
- Perspectives




# PULMONARY VS. SYSTEMIC CIRCULATION

## PULMONARY CIRCULATION



## SYSTEMIC CIRCULATION



- Gaz exchange
- *shorter* and wider circulation:  
=> lower flow rate
- **thin** artery walls and **few** smooth muscle fibers
- $PVR = (PAP - LAP) / Q$   
~ 1,6 mmHg



- Transport
- Wide and multi-organ
- **thick** artery walls and **many** smooth muscle fibers
- $SVR = (SAP - RAP) / Q$   
~ 16,5 mmHg



# RIGHT VENTRICLE-PULMONARY CIRCULATION UNIT

## Determinant of RV afterload

- RV pre-load
- RV dimension and geometry,
- myocytes mechanics



High compliant wall and Low resistance

Distensible arteries, accommodating the entire Q with low increase in pressure

# REGULATORY DETERMINANTS


## SYSTEMIC CIRCULATION

- autonomic nervous system (baroreflex, ...)
- metabolic demand
- temperature
- hormonal signals



## PULMONARY CIRCULATION

- hypoxia
- exercise
- acid/base balance and CO<sub>2</sub> levels
- alveolar & intrapleural pressures
- autonomic nervous system
- NO, Endothelin, Prostacyclin
- Inflammatory Mediators

## HYPOXIC PULMONARY VASOCONSTRICTION



**Chronic Hypoxia**  
 Rho kinase activation  
 HIF activation  
 Sensibilisation of Ca<sup>++</sup>




SMC contraction strenghtening  
 Pulmonary vascular remodeling  
 Pulmonary Hypertension

# Right ventricular dyssynchrony during hypoxic breathing but not during exercise in healthy subjects: a speckle tracking echocardiography study


**Right ventricular speckle tracking:**  
 (SD of strain-time curves of 4 RV segments)  
**17 healthy subjects**  
 - Normoxic aerobic exercise  
 - Acute hypoxia FiO2: 0.12

BASELINE REST NORMOXIA



mPAP 14 mmHg  
 PVR 1.3 WU  
 RV-SD4 7 ms


EFFORT NORMOXIA 100 W



mPAP 26 mmHg  
 PVR 1.31 WU  
 RV-SD4 6 ms


Reduction of PVR

BASELINE REST NORMOXIA



mPAP 11 mmHg  
 PVR 1.02 WU  
 RV-SD4 10 ms

REST HYPOXIA 45 MIN



mPAP 18 mmHg  
 PVR 1.58 WU  
 RV-SD4 30 ms

Increase of PVR

Hypoxic exposure, not exercise, is associated with a marked regional inhomogeneity of RV contraction HPV? Hypoxia?




# PLAN

- ✓ Introduction
- High-Altitude
- Highlanders
- Moderate altitude
- Normoxia
- Athletes
- Perspectives



# VO<sub>2</sub>max paradox

- △ Acute hypoxia
- Chronic hypoxia
- Operation Everest II
- ◇ Operation Everest III
- ▼ High Altitude Natives






# Fick Principle

$$VO_2\max = Q \max \times (C_aO_2 - C_vO_2)\max$$

At 5300m,  $VO_2\max$  reduction: 1/3  $Q\max$  limitation + 2/3:  $CaO_2\max$  reduction

## HRmax


HRmax (bpm)




restoration by para-sympathetic blockage does not increase  $Q\max$  or  $VO_2\max$

Placebo Glycopyrrolate


$Q\max$  (l/min)



$VO_2\max$  (l/min)




Placebo Glycopyrrolate




## SVmax

Psyst / LV ESV, mmHg/ml




rest Max exercise

Calbet et coll. *Am J Physiol.* 2003




↓  $CaO_2$  with altitude but is normalised through acclimatisation to an altitude of ~5000 m

# Increased Pap during high-altitude exposure limits exercise capacity, by increasing RV afterload/work and limiting maximal cardiac output



# Pulmonary vasodilation increases exercise capacity probably by reducing right ventricle afterload and increase maximal cardiac output in hypoxia








	<b><u>NORMOXIA</u></b>	<b><u>ACUTE HYPOXIA</u></b> (FiO <sub>2</sub> : 0,10)		<b><u>CHRONIC HYPOXIA</u></b> (5240m)	
	<b>baseline</b>	<b>placebo</b>	<b>sildenafil</b>	<b>placebo</b>	<b>sildenafil</b>
<b>sPap peak, mmHg</b>	<b>25</b>	<b>43</b>	<b>36**</b>	<b>34</b>	<b>28*</b>
<b>Load max, W</b>	<b>263</b>	<b>131</b>	<b>173**</b>	<b>171</b>	<b>190*</b>
<b>SaO<sub>2</sub> peak, %</b>	<b>98</b>	<b>61</b>	<b>67**</b>	<b>72</b>	<b>71</b>



# Sildenafil Inhibits Altitude-induced Hypoxemia and Pulmonary Hypertension

Jean-Paul Richalet, Pierre Gratadour, Paul Robach, Isabelle Pham, Michèle Déchaux, Aude Joncquiert-Latarjet, Pascal Mollard, Julien Brugniaux, and Jérémy Cornolo




# Effects of Sildenafil on Exercise Capacity in Hypoxic Normal Subjects

VITALIE FAORO,<sup>1</sup> MICHEL LAMOTTE,<sup>2</sup> GAEL DEBOECK,<sup>1</sup>  
ADRIANA PAVELESCU,<sup>2</sup> SANDRINE HUEZ,<sup>2</sup> HERVÉ GUENARD,<sup>3</sup>  
JEAN-BENOÎT MARTINOT,<sup>4</sup> and ROBERT NAEIJE<sup>1</sup>

14 healthy subjects  
1h after 50mg sildenafil/placebo  
double-blind, cross-over




CPET and Stress-Echo  
in 6 conditions =>




Normoxia + 1h normobaric hypoxia (FiO2:0.10)



mPAP and LAP at increasing Q




Chronic Hypoxia  
After acclimatation  
5000m, Chimborazo, Equator







# Results





- N- Normoxia
- △ HA - Hypoxie acute normobaric
- ▽ HC - Hypoxia chronic hypobaric
- P - placebo
- S - sildenafil

**Sildenafil: limit the hypoxic decrease in VO<sub>2</sub>max  
Increased O<sub>2</sub> delivery or hemodynamic effect?**




# Other pharmacological agents ?

**Bosentan, a non-selective endothelin receptor antagonist, inhibits HPV**



Modesti et coll. *Circulation* 2006

11 healthy subjects  
 Bosentan (2x62,5mg/24h et 4x125mg/48h)  
 Cross-over double-blind  
 Normoxia vs acute hypoxia (FiO<sub>2</sub>: 0.12)



**Moderate hypoxic pulmonary hypertension partially contributes to decreased VO<sub>2</sub>max at high altitude**

Faoro et al. *Chest* 2009



# Pulmonary artery pressure limits exercise capacity at high altitude

R. Naeije\*, S. Huez#, M. Lamotte#, K. Retailleau†, S. Neupane+, D. Abramowicz§ and V. Faoro\*



Pyramid hut, 5050m, Nepal

**22 healthy subjects**  
**Sitaxentan (100mg/day during 7 days)**  
**vs placebo (double-blind)**  
**Cross over in acute hypoxia (FIO<sub>2</sub>:0.12)**  
**Randomized in chronic hypoxia**




**pulmonary vasodilation has positive effect on aerobic capacity, but this is particularly true in acute hypoxic condition which reduced effect in chronic hypoxia.**




# Still under debate...

- Effect with Dexamethazone in HAPE-suceptible subjects
- Numerous confounding factors (Side effects? Acetazolamide?, Environment, ...)
- Controvesial data ...
- No pure pharmacological VPH inhibitor ( $\Delta SpO_2?$ )



38 healthy subjects => Sea level and 5-10 days 3800m



Stembridge et al. J Physiol 2019

J Appl Physiol 112: 20–25, 2012.  
First published October 6, 2011; doi:10.1152/jappphysiol.00670.2011.


Improvement in lung diffusion by endothelin A receptor blockade at high altitude

Claire de Bisschop,<sup>1</sup> Jean-Benoit Martinot,<sup>2</sup> Gil Leurquin-Sterk,<sup>3</sup> Vitalie Faoro,<sup>3</sup> Hervé Guénard,<sup>4</sup>

	Sitaxsentan (n = 11)			
	Baseline		After 7 Days	
	Rest	30 min PE	Rest	30 min PE
$DL_{CO}$ , $ml \cdot min^{-1} \cdot mmHg^{-1}$	$36 \pm 3$	$35 \pm 2$	$36 \pm 2$	$38 \pm 3$
$DL_{NO}$ , $ml \cdot min^{-1} \cdot mmHg^{-1}$	$155 \pm 12$	$145 \pm 11^*$	$168 \pm 11\#$	$156 \pm 11^*\#$
$Dm$ , $ml \cdot min^{-1} \cdot mmHg^{-1}$	$79 \pm 6$	$74 \pm 6^*$	$85 \pm 6\#$	$79 \pm 5^*\#$
$V_c$ , ml	$100 \pm 10$	$102 \pm 9$	$97 \pm 8$	$111 \pm 10$

Fischer et al. Am J Respir Crit Care Med 2009

# Membrane and Capillary component of diffusion capacity



**Single breath method :  $D_L$  of 2 gases, NO and CO**

**Quantification of capillary blood volume ( $V_c$ ) and membrane component ( $D_m$ ) to diffusing capacity**

$$1/D_{LNO} = 1/D_{mNO} + 1/\theta Vc$$

$$1/D_{LCO} = 1/D_{mCO} + 1/\theta Vc$$

$$\frac{1}{D_L} = \frac{1}{D_m} + \frac{1}{\theta \cdot Vc}$$

**$D_{LNO}$  essentially dependant on membrane resistance**

**$\downarrow D_{LNO} / D_{LCO}$**   
 indicates more increase in  $Vc$  compared to  $D_m$

# PLAN

- ✓ Introduction
- ✓ High-Altitude
- Highlanders
- Moderate altitude
- Normoxia
- Athletes
- Perspectives





# Highlanders



## Tibetans

- ↑ diffusion capacity
- ↑ VE
- ↓ Hb
- ↓ SaO<sub>2</sub>
- ↓ Pap

## Andeans

- ↓ VE
  - ↑ Hb
  - ↑ Pap
  - ↑ SaO<sub>2</sub>
- Especially in CMS

**Different phenotypes**






# Andeans

Variable	All		
	Value	% SL pred.	P-value
PcapO <sub>2</sub> (mmHg)	63 ± 11	-	NS
TL <sub>COcor</sub> (mL.min <sup>-1</sup> mmHg <sup>-1</sup> )	50 ± 14	159 ± 35	0.004
TL <sub>NO</sub> (mL.min <sup>-1</sup> mmHg <sup>-1</sup> )	180 ± 53	119 ± 75	0.02
Dm <sub>CO</sub> (mL.min <sup>-1</sup> mmHg <sup>-1</sup> )	92 ± 27	119 ± 75	0.02
V <sub>Ccor</sub> (ml)	180 ± 54	191 ± 49	0.001
VA (L)	6.6 ± 1.3	110 ± 20	NS
TL <sub>NO</sub> /TL <sub>COcor</sub>	3.6 ± 0.3	-	0.038

**- high diffusing capacity:  
probably reflecting pulmonary  
capillary distension but also explained  
by an increased amount of vessel**

**-- hypoxia-induced angiogenesis?**



# Pulmonary circulation and gas exchange at exercise in Sherpas at high altitude

Vitalie Faoro,<sup>1</sup> Sandrine Huez,<sup>2</sup> Rebecca Vanderpool,<sup>3</sup> Herman Groepenhoff,<sup>4</sup> Claire de Bisschop,<sup>5</sup> Jean-Benoît Martinot,<sup>6</sup> Michel Lamotte,<sup>2</sup> Adriana Pavelescu,<sup>3</sup> Hervé Guénard,<sup>7</sup> and Robert Naeije<sup>1,3</sup>




**13 healthy Sherpas  
vs 13 acclimatized lowlanders  
Altitude: 5050m, Pyramid Hut**



# Pulmonary circulation and gas exchange at exercise in Sherpas at high altitude

Vitalie Faoro,<sup>1</sup> Sandrine Huez,<sup>2</sup> Rebecca Vanderpool,<sup>3</sup> Herman Groepenhoff,<sup>4</sup> Claire de Bisschop,<sup>5</sup> Jean-Benoît Martinot,<sup>6</sup> Michel Lamotte,<sup>2</sup> Adriana Pavelescu,<sup>3</sup> Hervé Guénard,<sup>7</sup> and Robert Naeije<sup>1,3</sup>

	Lowlanders (0 m)	Lowlanders (5,050 m)	Highlanders (5,050 m)
VA, liters	6.3 ± 0.4	6.6 ± 0.3*	7.4 ± 0.6
DL <sub>NO</sub> , ml·min <sup>-1</sup> ·mmHg <sup>-1</sup>	148 ± 11	153 ± 9	226 ± 18§
DL <sub>CO cor</sub> , ml·min <sup>-1</sup> ·mmHg <sup>-1</sup>	33 ± 2	37 ± 2†	61 ± 4§
DL <sub>NO</sub> /DL <sub>CO</sub>	4.5 ± 0.1	4.2 ± 0.1‡	3.7 ± 0.1§
PCO <sub>2</sub> , mmHg	109 ± 4	47 ± 1†	54 ± 1§



Sherpas: high gas exchange, decreased ventilatory response at exercise.  
Lower RV afterload with little HPV and polycytemia

# Inter-ethnic comparison

	<u>Lowlanders</u> <u>0m</u>	<u>Lowlanders</u> <u>4350-</u> <u>5050m</u>	<u>Sherpas</u> <u>5050m</u>	<u>Quechuas</u> <u>4350m</u>
<b>Hb, g/dl</b>	<b>13.9± 0.3</b>	<b>15.1± 0.3</b>	<b>15.9 ± 0.3</b>	<b>17.6 ± 0.5<sup>ooo</sup></b>
<b>SaO<sub>2</sub>, %</b>	<b>98± 1</b>	<b>86 ± 1</b>	<b>86 ± 1</b>	<b>90 ± 1<sup>o*</sup></b>
<b>mBP, mmHg</b>	<b>101±3</b>	<b>89±3</b>	<b>100±3<sup>\$</sup></b>	<b>98±3<sup>o</sup></b>
<b>DL<sub>NO</sub>, ml.min<sup>-1</sup>.mmHg<sup>-1</sup></b>	<b>148±11</b>	<b>153±9</b>	<b>226±18<sup>###</sup></b>	<b>204±11<sup>###o</sup></b>
<b>DL<sub>CO</sub><sup>COR</sup>,ml.min<sup>-1</sup>.mmHg<sup>-1</sup></b>	<b>33±2</b>	<b>37±2<sup>**</sup></b>	<b>61±4<sup>###</sup></b>	<b>55±3<sup>###oo</sup></b>
<b>DL<sub>NO</sub>/DL<sub>CO</sub></b>	<b>4.5±0.1</b>	<b>4.2±0.1<sup>***</sup></b>	<b>3.7±0.1<sup>###</sup></b>	<b>3.7±0.1<sup>###</sup></b>

\*: P < 0.05; Sherpa vs Quechua at high altitude

\$: P < 0.05, £££: P < 0.001; Sherpa vs Lowlanders at 4350 m

o: P < 0.05, ooo: P < 0.001; Quechua vs Lowlanders at 5050m



# Pap-Q relationships corrected for Hb





<u>Lowlanders</u> 4350-5050m	<u>Sherpas</u> 5050m	<u>Quechuas</u> 4350m
<b>5.2 ± 0.3</b>	<b>4.3 ± 0.5<sup>EE</sup></b>	<b>4.4 ± 0.3<sup>E</sup></b>

**Relative PVR at a hematocrit of 45% according to the exponential relationship between resistance and hematocrit**

$$R_0(45\%) = R_0 \frac{1}{\exp(2(\varphi - 0.45))}$$

$\varphi$ : hematocrit level

Linehan et al. JAP 1992



# Exercise capacity

	Lowlander 0m	Lowlander 5050m	Sherpas 5050m	Quechuas 4350m
<b>VO<sub>2</sub>max, ml.kg<sup>-1</sup>.min<sup>-1</sup></b>	<b>44±2</b>	<b>28±1***</b>	<b>32±3</b>	<b>32±2</b>
<b>HR max, bpm</b>	<b>186±3</b>	<b>162±4***</b>	<b>170±4</b>	<b>160 ± 4°</b>
<b>SaO<sub>2</sub>max, %</b>	<b>93±1</b>	<b>78±2***</b>	<b>81±3</b>	<b>88 ± 1##°°</b>
<b>RER max</b>	<b>1.24±0.03</b>	<b>1.20±0.03</b>	<b>1.30±0.03#</b>	<b>1.13±0.01#°°</b>
<b>V<sub>E</sub>max, l/min</b>	<b>114±7</b>	<b>128±9*</b>	<b>114±12</b>	<b>106 ± 8</b>
<b>V<sub>E</sub>/VCO<sub>2</sub>at AT</b>	<b>26±1</b>	<b>49±2***</b>	<b>44±1##</b>	<b>38±1###°°</b>

\*: Lowlanders at SL vs HA  
 #: Highlanders vs Lowlanders  
 °: Quechua vs Sherpa

“VO<sub>2</sub> paradox”: unremarkable aerobic exercise capacities contrasting with superior field performance of Andean or Tibetan natives at high altitudes.



# Chronic Mountain Sickness

13 CMH patients, [Hb]:  $24 \pm 1$  g/dl  
 15 Healthy Highlanders, [Hb]:  $18 \pm 1$  g/dl  
 15 Lowlanders at SL, [Hb]:  $15 \pm 1$  g/dl  
 4359m Cerro de Pasco, Peru



Groepenhoff et al. Chest 2012


Both diffusion capacity components increased similarly in highlanders with or without CMS at (However, Hb dependent values were increased by 15%)



# Decreased chemosensitivity

Measure	Patients With CMS	Highlanders
Power, W	137 ± 7 <sup>a</sup>	119 ± 9 <sup>a</sup>
Power, % reference	81 ± 4	92 ± 8
$\dot{V}O_2$ , % reference	102 ± 6	117 ± 13
$\dot{V}O_2$ , mL/min/kg	32 ± 1	32 ± 2
RER	1.13 ± 0.02	1.13 ± 0.01
$\dot{V}E/\dot{V}CO_2$ slope	32 ± 1 <sup>a,c</sup>	36 ± 1 <sup>a</sup>
$\dot{V}E$ , L/min	105 ± 8 <sup>a</sup>	106 ± 8 <sup>a</sup>
$\dot{V}E/MVV$ , %	70 ± 5	73 ± 6
HR, beat/min	145 ± 5 <sup>a,c</sup>	160 ± 4
HR, % reference	87 ± 3	93 ± 2
O <sub>2</sub> pulse, mL/beat	16 ± 1 <sup>c</sup>	12 ± 1 <sup>a</sup>
O <sub>2</sub> pulse, % reference	80 ± 3	77 ± 5
SpO <sub>2</sub> , %	82 ± 1 <sup>c</sup>	88 ± 1 <sup>a</sup>
CaO <sub>2</sub> , mL/dL	26 ± 1 <sup>a,c</sup>	21 ± 1 <sup>a</sup>
SBP, mm Hg	153 ± 6	148 ± 4
DBP, mm Hg	85 ± 3	83 ± 2

<sup>a</sup>P < .05 vs lowlanders at altitude.  
<sup>b</sup>P < .01 vs lowlanders at sea level.  
<sup>c</sup>P < .05 vs highlanders.



**More severe depression of chemosensitivity in CMS.  
 In keeping with the notion of a continuum of ventilatory responses from health to CMS**



# PLAN

- ✓ Introduction
- ✓ High-Altitude
- ✓ Highlanders
- Moderate altitude
- Normoxia
- Athletes
- Perspectives



# Pulmonary Vascular Function and Aerobic Exercise Capacity at Moderate Altitude

VITALIE FAORO<sup>1</sup>, GAEL DEBOECK<sup>1,2</sup>, MARCO VICENZI<sup>1,2,3</sup>, ANNE-FLEUR GASTON<sup>4</sup>, BAMODI SIMAGA<sup>1</sup>, GRÉGORY DOUCENDE<sup>4</sup>, ILONA HAPKOVA<sup>4</sup>, EMMA ROCA<sup>5</sup>, ENRIC SUBIRATS<sup>5,6</sup>, FABIENNE DURAND<sup>4</sup>,



**38 healthy and fit subjects**  
**Sea level**  
**2250m, Masella, Spain**  
**ECHO, DIFFUSION, CPET**


TABLE 1. Cardiopulmonary exercise testing at sea level and at 2250 m (N = 38).





	Sea Level	Moderate Altitude
Rest		
HR, bpm	61 ± 10	58 ± 6
SpO <sub>2</sub> , %	99 ± 1	95 ± 2***
CaO <sub>2</sub> , mL·dL <sup>-1</sup>	19.1 ± 1.6	18.6 ± 1.7***
Mean BP, mm Hg	85 ± 10	88 ± 10
Pet CO <sub>2</sub> , mm Hg	38 ± 2	36 ± 2***
Maximal exercise		
Mean BP, mm Hg	114 ± 16	117 ± 16
W, W	351 ± 69	317 ± 70***
VO <sub>2max</sub> , mL·min <sup>-1</sup> ·kg <sup>-1</sup>	51 ± 9	43 ± 8***
HR, bpm	176 ± 10	171 ± 9**
Ṡ <sub>E</sub> , L·min <sup>-1</sup>	136 ± 32	134 ± 36
Pet CO <sub>2</sub> , mm Hg	36 ± 3	33 ± 3***
RER	1.18 ± 0.09	1.27 ± 0.12***
SpO <sub>2</sub> , %	95 ± 3	85 ± 5***
O <sub>2</sub> pulse, mL per beat	22 ± 5	19 ± 5***
Ṡ <sub>E</sub> /V̇CO <sub>2</sub> at AT	28 ± 3	30 ± 3***
VO <sub>2</sub> at AT, % VO <sub>2max</sub>	68 ± 8	66 ± 8

SpO<sub>2</sub>, arterial oxygen saturation; CaO<sub>2</sub>, arterial O<sub>2</sub> content; W, maximum workload; VO<sub>2max</sub>, maximum O<sub>2</sub> uptake; Ṡ<sub>E</sub>, ventilation; SpO<sub>2</sub>, pulse oximetry O<sub>2</sub> saturation; V̇CO<sub>2</sub>: CO<sub>2</sub> output.

\*\*P < 0.01, moderate altitude vs sea level.

\*\*\*P < 0.001, moderate altitude vs sea level.





Aerobic exercise capacity at sea level as well as at moderate altitude is modulated by pulmonary vascular reserve, but essentially determined by O<sub>2</sub> delivery to the tissues at moderate altitude more than at sea level.




# PLAN




- ✓ Introduction
- ✓ High-Altitude
- ✓ Highlanders
- ✓ Moderate altitude
- Normoxia
- Athletes
- Perspectives




# Does pulmonary circulation limits exercise capacity at sea level?




Low Pulmonary Transit of Agitated Contrast (PTAC)



High Pulmonary Transit of Agitated Contrast (PTAC)



Positive PTAC probably reflects pulmonary arteriolar and capillary distension => participation of decrease PVR at exercise



Participation of capillary distension to decreased PVR

$p < 0.0001$  Theory of « pulmonary vascular reserve »

# Pulmonary vascular distensibility predicts aerobic capacity in healthy individuals

Sophie Lalande, Patrick Yerly, Vitalie Faoro and Robert Naeije

In healthy individuals, higher maximal aerobic capacity is associated with greater pulmonary vascular distensibility and lower pulmonary vascular resistance

24 healthy subjects









Figure 4. Relationships between maximal aerobic capacity ( $\dot{V}_{O_2\max}$ ) and its independent predictors resting values of pulmonary capillary blood volume ( $V_c$ ) (A) and maximal exercise values of total pulmonary vascular resistance index (PVRI) (B)

# Pulmonary Vascular Reserve and Exercise Capacity at Sea Level and at High Altitude

64 healthy lowlanders  
Sea level +  
Altitude 4350 – 5050m

## Independent predictors of aerobic capacity



**At sea level and high altitude, a higher “pulmonary vascular reserve” allows for superior exercise capacity at lower ventilatory cost**

# PLAN





- ✓ Introduction
- ✓ High-Altitude
- ✓ Highlanders
- ✓ Moderate altitude
- ✓ Normoxia
- Athletes
- Perspectives



# Athletic pulmonary circulation

**Table 1.** Right ventricular function and pulmonary haemodynamics at rest and during exercise in healthy subjects versus athletes.

Parameters	Healthy		Athletes	
	Rest	Peak exercise	Rest	Peak exercise
<b>RV function</b>				
TAPSE (mm)	>16	↑	—	↑
RV ejection fraction (%)	>50	↑	-/↓	↑
<b>Pulmonary haemodynamics</b>				
CO (L/min)	4–8	↑	-/↑	↑↑
PASP (mmHg)	<36	↑	-/↑	↑↑
RAP (mmHg)	3–5	↑	—	↑
mPAP (mmHg)	<25	↑	-/↑	↑↑
PVR (WU)	<3	↓	—	↓
PAWP (mmHg)	<15	—	—	↑



La Gerche A, Ferrara F, D'Andrea A, Bossone E. **Pulmonary vascular remodelling in athletes: an anti-concept to be proved.** *Eur J Prev Cardiol.* 2020

Claessen G, et al. *JACC Cardiovasc Imaging* 2016


# Exercise and the right ventricle: a potential Achilles' heel

Andre La Gerche<sup>1,2,3\*</sup>, Dhruvo J. Rakshit<sup>1,4</sup>, and Guido Claessen<sup>2</sup>



Cardiac MRI during exercise: RV dilatation and diastolic i


La Gerche, Circ Cardiovasc Imag 2013; 6: 329-38





**Repeated or high increase in RV afterload during high-intensity exercise may become a critical constraint**

Increased RV load/afterload => RV dilation (+ delay in contraction) => septal shift toward LV => attenuate early diastolic filling of the LV => further increase LA pressures => Arrhythmogenic RV cardiomyopathy?

# Increased pulmonary vascular distensibility



Poon-transform of mPAP = f(CO)







**Curvi-linear model:**

$$P_a = \frac{[(1 + \alpha P_v)^5 + 5\alpha R_0 \dot{Q}]^{1/5} - 1}{\alpha}$$

Sedentary: R<sub>0</sub> = 2.776 mmHg.min/l; α = 1.09%  
 Players: R<sub>0</sub> = 2.957 mmHg.min/l; α = 1.28%

# Increased pulmonary vascular distensibility



Higher  $\alpha_{pulm}$  allows a better RV-arterial coupling at exercise which may be an advantage to reach higher aerobic capacity




# PLAN


- ✓ Introduction
- ✓ High-Altitude
- ✓ Highlanders
- ✓ Moderate altitude
- ✓ Normoxia
- ✓ Athletes
- Perspectives



# ONGOING PROJECTS



- Longitudinal effects of aerobic training (HIIT) on the RV-pulmonary vascular unit



- Effects of menstrual cycle and contraception on the cardiovascular adaptation to exercise

- Migrated Sherpas to Belgium: first and second generation



## CONCLUSION

## FIENDS


- Well **adapted** to moderate to intense physical exercise, without extreme elevation of Pap, thanks to its arteriolar **distensibility** and **recruitability**.
- HPV will lead to **moderate HP**
- Wide **pulmonary vascular reserve** contributes to higher aerobic capacity with better gaz exchange
- **Sherpas** have little HPV and large Vc
- Athletes have a higher pulmonary vascular **distensibility**

## FOES

- Wide inter-subject **variability**
- Limits exercise capacity, particularly at **high-altitude**
- Suceptible subjects
- **Andeans** have higher PVR < increased in **CMH**
- But **high volume of training** at high Q may affect RV function



# Thank you!



Pr Van De Born



Pr Moraine



Pr Naeije

The team...



Cyril Tordeur



Jérémy Rabineau



Paniz Balali



Elza Abdessater



Marine Carpentier



Bert Celie

**Laboratory of Cardiorespiratory Exercise Physiology, FSM, ULB**  
**Laboratory of Physics and Physiology – Dpt Cardiology, Erasme Hospital**






Figure 2 – Correlation for mean mPAP with  $\Delta\text{SpO}_2$  during exercise. The solid line represents the linear regression of the present correlation ( $r = -0.60$ ;  $P = .002$ ). This graphic illustrates that an mPAP value exceeding a threshold of 42 mm Hg (long dashed line) at maximal exercise is reached in all athletes with arterial oxygen desaturation. mPAP = maximal pulmonary arterial pressure. See Figure 1 legend for expansion of other abbreviations.

# Training and PH


- **Exercise-induced pulmonary vasoconstriction** may occur in some patients with pulmonary hypertension (Kulik 1983).
- However, exercise in patients with pulmonary hypertension can lead to **sharp increases in pulmonary artery pressure and a limitation of aerobic capacity** (Naeije 2012).
- Aerobic exercise training has been shown to be effective in **reducing fatigue and increasing physical activity** in patients with pulmonary arterial hypertension (PAH) (Weinstein 2013).
- It may also have a beneficial effect on PAH by **attenuating arterial pulmonary hypertension** (Madonna 2016).
- Despite potential risks, **exercise training has been found to improve exercise capacity, quality of life, muscle function, and pulmonary circulation in PAH patients** (Vecchia 2018).
- The optimal intensity of aerobic exercise for improving exercise capacity and quality of life in PAH patients is still under investigation (Seo 2021).

# Athletic pulmonary circulation remodeling

**Table 1.** Right ventricular function and pulmonary haemodynamics at rest and during exercise in healthy subjects versus athletes.

Parameters	Healthy		Athletes	
	Rest	Peak exercise	Rest	Peak exercise
<b>RV function</b>				
TAPSE (mm)	>16	↑	—	↑
RV ejection fraction (%)	>50	↑	—/↓	↑
<b>Pulmonary haemodynamics</b>				
CO (L/min)	4–8	↑	—/↑	↑↑
PASP (mmHg)	<36	↑	—/↑	↑↑
RAP (mmHg)	3–5	↑	—	↑
mPAP (mmHg)	<25	↑	—/↑	↑↑
PVR (WU)	<3	↓	—	↓
PAWP (mmHg)	<15	—	—	↑

CO: cardiac output; mPAP: mean pulmonary artery pressure; PASP: pulmonary artery systolic pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; RAP: right atrial pressure; RV: right ventricular; TAPSE: tricuspid annular plane systolic exertion; WU: woods unit; —: similar to healthy subjects; arrows black: higher; arrows white: slightly higher or reduced.



Claessen G, La Gerche A, Voigt JU, et al. Accuracy of echocardiography to evaluate pulmonary vascular and RV function during exercise. *JACC Cardiovasc Imaging* 2016; 9: 532–543.

La Gerche A, Ferrara F, D'Andrea A, Bossone E. Pulmonary vascular remodelling in athletes: an anti-concept to be proved. *Eur J Prev Cardiol.* 2020 Apr;27(6):649-650.

# CONCLUSIONS



FRIENDS

FOES

## RECRUTEMENT and DISTENSION

High altitude dwellers and sojourners who are able to maintain a higher  $\dot{V}_{O_2}$  at high altitude have a higher **“pulmonary vascular reserve”** defined as, a combination of low pulmonary vascular resistance and high lung diffusing capacity.

Wide inter-individual variation

The aerobic exercise profile of life-long high altitude adaptation observed in the Quechua includes a combination of:

- **markedly increased lung diffusion capacity**
- **decreased ventilatory response**

With, as difference;

- **higher hemoglobin in Quechua**